Results 191 to 200 of about 1,741,453 (344)

Early metastasis is characterized by Gr1+ cell dysregulation and is inhibited by immunomodulatory nanoparticles

Molecular Oncology, EarlyView.
Breast cancer metastasis is associated with myeloid cell dysregulation and the lung‐specific accumulation of tumor‐supportive Gr1+ cells. Gr1+ cells support metastasis, in part, through a CHI3L1‐mediated mechanism, which can be targeted and inhibited with cargo‐free, polymeric nanoparticles.
Jeffrey A. Ma, Sophia M. Orbach, Kate V. Griffin, Kathryn Kang, Yining Zhang, Rebecca S. Pereles, Ian A. Schrack, Guillermo Escalona, Jacqueline S. Jeruss, Lonnie D. Shea   +9 more
wiley   +1 more source

Radiation-Force Assisted Targeting Facilitates Ultrasonic Molecular Imaging [PDF]

, 2004
Shukui Zhao, Mark A. Borden, Susannah H. Bloch, Dustin E. Kruse, Katherine W. Ferrara, Paul A. Dayton   +5 more
openalex   +3 more sources

Advances in Molecular Imaging of VEGFRs: Innovations in Imaging and Therapeutics. [PDF]

Int J Mol Sci
Karimi H, Lee S, Xu W, Langhans SA, Johnson DK, Stauff E, Kecskemethy HH, Averill LW, Yue X.   +8 more
europepmc   +1 more source

Molecular Imaging: Unveiling Metabolic Abnormalities in Pancreatic Cancer. [PDF]

Int J Mol Sci
Wang H, Gui Y, Lv K.
europepmc   +1 more source

Quantification of molecular and anatomical target contours of head and neck cancer to facilitate image-guided therapy during IMRT [PDF]

, 2003
Christopher Scarfone, William C. Lavely, Anthony J. Cmelak, Dominique Delbeke, William H. Martin, Dean Billheimer, Dennis E. Hallahan   +6 more
openalex   +1 more source

Loss of proton‐sensing GPR4 reduces tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
G protein‐coupled receptor 4 (GPR4) is a pH‐sensing receptor activated by acidic pH. GPR4 expression is increased in patients with inflammatory bowel disease who are at high risk of developing colorectal cancer. In mouse models, loss of GPR4 attenuated tumor progression. This correlated with increased IL2 and natural killer cell activity.
Leonie Perren, Moana Busch, Pedro A. Ruiz, Ermanno Malagola, Valeria Baumeler, Federica Foti, Adelina Gross, Tobias Grütter, Hendrik Edel, Cordelia Schuler, Kristina Handler, Glenn De Lange, Isabelle C. Arnold, Cheryl de Vallière, Klaus Seuwen, Martin Hausmann, Gerhard Rogler   +16 more
wiley   +1 more source

Advances in Molecular Imaging for the Early Detection and Management of Alzheimer's Disease. [PDF]

Cureus
Goel SA, Singh R, John DR, Suthar P, Singh JS.   +4 more
europepmc   +1 more source

Molecular Markers Of Different Elemental Compositions Bioengineered For Simultaneous Detection And Localization Of Multiple Biomolecules With Energy And Wavelength Dispersive Spectroscopic Imaging [PDF]

, 2003
Marek Malecki, R.J. Casper, R.K. Noll, D.A. Meyer, Ralph M. Albrecht   +4 more
openalex   +1 more source

TRPM8 levels determine tumor vulnerability to channel agonists

Molecular Oncology, EarlyView.
TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo, Francesco Giuseppe Carbone, Kristi Buzo, Nicole Annesi, Sacha Genovesi, Annalisa Lorenzato, Karen Widmann, Michela Libergoli, Elisa Marmocchi, Giovanni Bertalot, Alberto Brolese, Mauro Giulio Papotti, Luca Molinaro, Orazio Caffo, Mattia Barbareschi, Alberto Bardelli, Alessandro Romanel, Sabrina Arena, Andrea Lunardi   +18 more
wiley   +1 more source

Coelenterazine Analogs for Bioassays and Molecular Imaging. [PDF]

Sensors (Basel)
Kim SB, Kamiya G, Furuta T, Maki SA.
europepmc   +1 more source